Jaime Cordero-Ramos

Jaime Cordero-Ramos

Auto-generated profile, based on publicly available information

Jaime Cordero-Ramos

Hospital Pharmacy Central Management, Extremadura Health Service, Seville, Spain

Research Focus & Metrics

Academic Career Length

17Years (2010-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 February 2024 in Farmacia Hospitalaria
Verified
Journal Article
Open access
LALaura Amaro-Álvarez
Laura Amaro-Álvarez
JCJaime Cordero-Ramos
Jaime Cordero-Ramos
MCMiguel Ángel Calleja-Hernández
Miguel Ángel Calleja-Hernández
Pharmacogenetics evaluates how genetic variations influence drug responses. Nowadays, genetic tests have advanced, becoming more affordable, and its integration is supported by stronger clinical evidence. Guidelines such as those from CPIC (Clinical Pharmacogenetics Implementation Consortium) and resources like PharmGKB facilitate genotype-based prescribing; and organizations like the FDA promote genetic testing before initiating certain medications. Preventive pharmacogenetic panels seem promising, but further research on biomarkers and diverse populations is needed. The aim of this review is to analyze recent evidence on the genotype-drug response relationship to examine how the genetic profile of patients influences the clinical response to treatments, and analyze the areas of research that need further study to advance towards a genetic-based precision medicine. A systematic search was conducted on PubMed to identify articles investigating the genotype-drug response relationship. The search strategy included terms such as "pharmacogenetics", "personalized treatment", "precision medicine", "dose adjustment", "individualizing dosing", "clinical routine", and "clinical practice." Clinical trials, observational studies, and meta-analyses published in English or Spanish between 2013 and 2023 were included. The initial search resulted in a total of 136 articles for analysis. 49 articles were included for the final analysis following review by 2 investigators. A relationship between genetic polymorphisms and drug response or toxicity was found for drugs such as opioids, GLP-1 agonists, tacrolimus, oral anticoagulants, antineoplastics, atypical antipsychotics, efavirenz, clopidogrel, lamotrigine, anti-TNFα agents, voriconazole, antidepressants, or statins. However, for drugs like metformin, quetiapine, irinotecan, bisoprolol, and anti-VEGF agents, no statistically significant association between genotype and response was found. The studies analyzed in this review suggest a strong correlation between genetic variability and individual drug responses, supporting the use of pharmacogenetics for treatment optimization. However, for certain drugs like metformin or quetiapine, the influence of genotype on their response remains unclear. More studies with larger sample sizes, greater ethnic diversity, and consideration of non-genetic factors are needed. The lack of standardization in analysis methods and accessibility to genetic testing are significant challenges in this field. As a conclusion, pharmacogenetics shows immense potential in personalized medicine, but further research is required.

23 October 2018 in International Journal of Technology Assessment in Health Care
Verified
Journal Article
Closed access
PDF file
ÚRÚrsula Baños Roldán
Úrsula Baños Roldán
XBXavier Badia
Xavier Badia
JMJose Antonio Marcos-Rodríguez
Jose Antonio Marcos-Rodríguez
LCLuis De la Cruz-Merino
Luis De la Cruz-Merino
JGJaime Gómez-González
Jaime Gómez-González
MCMiguel Ángel Calleja-Hernández
Miguel Ángel Calleja-Hernández
Objectives:The aim of this study was to develop and to assess a specific Multi-Criteria Decision Analysis (MCDA) framework to evaluate new drugs in an hospital pharmacy and therapeutics committee (P&TC) setting.Methods:A pilot criteria framework was developed based on the EVIDEM (Evidence and Value: Impact on DEcisionMaking) framework, together with other relevant criteria, and assessed by a group of P&TC's members. The weighting of included criteria was done using a 5-point weighting technique. Two drugs were chosen by evaluation: an orphan-drug for Gaucher disease, and a nonorphan drug for the treatment of inflammatory bowel disease. Evidence matrices were developed, and value contribution of each drug was evaluated by P&TC's members. An agreed final framework was obtained through a discussion between the P&TC's members.Results:After criteria assessment, the pilot framework included eight quantitative criteria: “disease severity,” “unmet needs,” “comparative efficacy/effectiveness,” “comparative safety/tolerability,” “comparative patient-reported outcomes,” “comparative cost consequences-cost of treatment,” “comparative cost consequences-other medical costs,” and “quality of evidence”; and one contextual criterion: “opportunity costs and affordability.” The most valued criteria were: “comparative safety/tolerability,” “disease severity,” and “comparative efficacy/effectiveness.” When assessing the drugs most valued characteristics of the MCDA were the possibility that all team may contribute to drug assessment by means of scoring the matrices and the discussion to reach a consensus in drug positioning and value decision making.Conclusions:The reflective MCDA would integrate quantitative and qualitative criteria relevant for a P&TC setting, allowing reflective discussions based on the criteria weighting score.

1 July 2010 in European Journal Of Dermatology
Verified
Journal Article
Open access
PDF file
SLSara Lestre
Sara Lestre
JRJaime Ramos
Jaime Ramos
AJAlexandre João
Alexandre João
VSVasco Serrão
Vasco Serrão

27 January 2022 in Nursing in Critical Care
Verified
Journal Article
Closed access
PDF file
MNMARIA NUÑEZ NUÑEZ
MARIA NUÑEZ NUÑEZ
MMManuel Murillo‐Izquierdo
Manuel Murillo‐Izquierdo
MMMarisa Moya‐Martin
Marisa Moya‐Martin
MHMalvina Hoxha
Malvina Hoxha
MPM. Teresa Quesada Pérez
M. Teresa Quesada Pérez
SFSantiago Sandoval Fernández‐Del‐Castillo
Santiago Sandoval Fernández‐Del‐Castillo

4 January 2022 in Expert Review of Vaccines
Verified
Journal Article
Closed access
MVMarta (M) Valera-Rubio
Marta (M) Valera-Rubio
MSMaría Isabel (Mi) Sierra-Torres
María Isabel (Mi) Sierra-Torres
RGRaquel (R) Castillejo García
Raquel (R) Castillejo García
JCJaime (J) Cordero-Ramos
Jaime (J) Cordero-Ramos
MLMaría Reyes (Mr) López-Márquez
María Reyes (Mr) López-Márquez
MCMiguel Ángel (Ma) Calleja-Hernández
Miguel Ángel (Ma) Calleja-Hernández
The World Health Organization declared COVID-19 a pandemic in March 2020. The first vaccine became available in December, with practically no post-marketing data. An analytical cross-sectional survey-based study was conducted in a third-level hospital in Spain between March and April 2021 to describe the difference in adverse events with the BNT162b2 and mRNA-1273 COVID-19 vaccines. The participants were hospital workers who completed a survey voluntarily at least 14 days after the last vaccine. The STROBE checklist was followed. One thousand two hundred and forty-nine respondents completed the survey; 48% (599) received mRNA-1273 and 52% (650) BNT162b2. Fourteen thousand four hundred and two adverse reactions were recorded, 6896 local (3939 with mRNA-1273 and 2957 with BNT162b2 (6.6 vs 4.4 reactions per patient)) and 7506 systemic (4460 with mRNA-1273 and 3046 with BNT162b2 (7.4 vs 4.7 per patient)). Local reactions were more frequent after the first dose, while systemic reactions were higher after the second, for both vaccines and in a higher percentage with mRNA-1273 compared to BNT162b2 (p-value<0.05). Licensed mRNA vaccines were highly safe when administered under post-marketing conditions among working-age adults. The main adverse events were mild, although they occurred in most patients, especially after the mRNA-1273 vaccine.

4 January 2022 in The Journal of Dermatology
Verified
Journal Article
Closed access
PDF file
JCJaime Cordero‐Ramos
Jaime Cordero‐Ramos
RBRubén Barros‐Tornay
Rubén Barros‐Tornay
TTTomás Toledo‐Pastrana
Tomás Toledo‐Pastrana
LFLara Ferrándiz
Lara Ferrándiz
MCMiguel Ángel Calleja‐Hernández
Miguel Ángel Calleja‐Hernández
DMDavid Moreno-Ramírez
David Moreno-Ramírez